246 related articles for article (PubMed ID: 38396367)
21. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma.
Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K
Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407
[TBL] [Abstract][Full Text] [Related]
22. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
23. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
24. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
25. Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.
He H; Yang W; Huang Y; Zhang X; Peng Y; Yang Z
Angiogenesis; 2022 Feb; 25(1):5-8. PubMed ID: 34342748
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of
Tønnesen EMT; Stougaard M; Meldgaard P; Lade-Keller J
J Clin Pathol; 2023 Dec; 77(1):54-60. PubMed ID: 36410939
[TBL] [Abstract][Full Text] [Related]
27. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
[TBL] [Abstract][Full Text] [Related]
28. The correlation between programmed death-ligand 1 expression and driver gene mutations in NSCLC.
Yang H; Chen H; Luo S; Li L; Zhou S; Shen R; Lin H; Xie X
Oncotarget; 2017 Apr; 8(14):23517-23528. PubMed ID: 28423587
[TBL] [Abstract][Full Text] [Related]
29. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China.
Zheng Q; Huang Y; Zeng X; Chen X; Shao S; Jin Y; Xue Q; Wang Y; Guo Y; Gu B; Wu C; Li Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1547-1556. PubMed ID: 33196892
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK
Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
[TBL] [Abstract][Full Text] [Related]
32. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Wang CC; Huang KT; Chang HC; Tseng CC; Lai CH; Lan J; Liu TT; Huang CC; Lin MC
Thorac Cancer; 2022 Jan; 13(1):38-47. PubMed ID: 34841687
[TBL] [Abstract][Full Text] [Related]
33. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
34. Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Lee BS; Park DI; Lee DH; Lee JE; Yeo MK; Park YH; Lim DS; Choi W; Lee DH; Yoo G; Kim HB; Kang D; Moon JY; Jung SS; Kim JO; Cho SY; Park HS; Chung C
Biochem Biophys Res Commun; 2017 Sep; 491(2):493-499. PubMed ID: 28684311
[TBL] [Abstract][Full Text] [Related]
35. Dissecting the ferroptosis-related prognostic biomarker and immune microenvironment of driver gene-negative lung cancer.
Zhou R; Ma HC; Liu YH; Chen X; Chang XS; Chen YD; Liu LR; Li Y; Zhu YJ; Zhang HB
Exp Biol Med (Maywood); 2022 Aug; 247(16):1447-1465. PubMed ID: 35762414
[TBL] [Abstract][Full Text] [Related]
36. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
37. Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data.
Karatrasoglou EA; Chatziandreou I; Sakellariou S; Stamopoulos K; Kavantzas N; Lazaris AC; Korkolopoulou P; Saetta AA
Virchows Arch; 2020 Aug; 477(2):207-217. PubMed ID: 31989260
[TBL] [Abstract][Full Text] [Related]
38. Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
Schoenfeld AJ; Rizvi H; Bandlamudi C; Sauter JL; Travis WD; Rekhtman N; Plodkowski AJ; Perez-Johnston R; Sawan P; Beras A; Egger JV; Ladanyi M; Arbour KC; Rudin CM; Riely GJ; Taylor BS; Donoghue MTA; Hellmann MD
Ann Oncol; 2020 May; 31(5):599-608. PubMed ID: 32178965
[TBL] [Abstract][Full Text] [Related]
39. A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib.
Chen Y; Jiang B; He Y; Zhang C; Zhou W; Fang C; Gu D; Zhang M; Ji M; Shi J; Yang X
BMC Med Genomics; 2022 Jun; 15(1):141. PubMed ID: 35739536
[TBL] [Abstract][Full Text] [Related]
40. [A Real-world Study on the Assessment of Pathological Characteristics and Targeted Therapeutic Effect of Non-small Cell Lung Cancer Patients with Positive Driving Genes and High PD-L1 Expression].
Zhang H; Yang X; Li K; Wang J; Lv J; Li X; Zhang X; Qin N; Zhang Q; Wu Y; Ma L; Gai F; Hu Y; Zhang S
Zhongguo Fei Ai Za Zhi; 2021 Feb; 24(2):78-87. PubMed ID: 33478196
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
